ABIVAX (EPA:ABVX) | Finanzwire

Basculer en Français

11006	Companies
241147	Keywords
169718	Articles
129813	Press releases

Home
Companies
ABIVAX

PRESS RELEASE

published on 04/01/2026 at 22:05, 5 months 15 days ago

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
Abivax publishes financial reports with French and U.S. regulatory agencies, including Universal Registration Document and Annual Report. Company focuses on immune response in chronic inflammatory diseases with lead drug candidate in Phase 3 trials

Abivax Ulcerative Colitis Financial Reports Immune Response Regulatory Agencies
BRIEF

published on 03/27/2026 at 18:05, 5 months 20 days ago

ABIVAX: Details on Share Capital and Voting Rights as of February 28, 2026

Euronext Paris Share Capital Voting Rights Actions Abivax
BRIEF

published on 03/23/2026 at 21:10, 5 months 24 days ago

Abivax presents its 2025 results and outlook

Obefazimod Management Appointments 2025 Financial Results DSMB ABTECT Cash Flow 2027
BRIEF

published on 03/23/2026 at 21:10, 5 months 24 days ago

Abivax Reports Full Year 2025 Financial Results and Business Updates

Financial Results Biotechnology Obefazimod Clinical Trials Leadership Appointments
PRESS RELEASE

published on 03/23/2026 at 21:05, 5 months 24 days ago

Abivax Announces Full Year 2025 Financial Results and Provides Business Updates
Abivax reports full year 2025 financial results and key business updates, including safety updates, pivotal Phase 3 trial progress, senior leadership appointments, and upcoming milestones. Strong cash position and strategic plans highlighted

Financial Results Abivax Phase 3 Trial Leadership Appointments Business Updates
BRIEF

published on 02/26/2026 at 18:05, 6 months 18 days ago

ABIVAX: Update on Share Capital and Voting Rights

Euronext Paris Share Capital Voting Rights Shares Abivax
BRIEF

published on 02/21/2026 at 12:05, 6 months 23 days ago

Abivax Unveils Promising Obefazimod Data at ECCO 2026

Obefazimod Clinical Efficacy Safety Profile Inflammatory Bowel Disease Anti-Fibrotic Activity
PRESS RELEASE

published on 02/21/2026 at 12:00, 6 months 23 days ago

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
Abivax presents first evidence of anti-fibrotic activity for Obefazimod and new clinical efficacy and safety analyses in inflammatory bowel disease at ECCO 2026

Abivax Obefazimod Clinical Efficacy Inflammatory Bowel Disease Anti-fibrotic
BRIEF

published on 01/26/2026 at 18:05, 7 months 21 days ago

ABIVAX: Share capital and voting rights as of December 31, 2025

Voting Rights Biotechnology Actions AMF Abivax
BRIEF

published on 01/07/2026 at 22:10, 8 months 9 days ago

Abivax unveils its objectives for 2026

Abivax Obefazimod Phase 3 2026 RCH

Accesswire

Published on 09/16/2026 at 23:45, 7 hours 33 minutes ago

Galway Metals Settles Claim by Former Employee with Cash and Share Payments
Published on 09/16/2026 at 21:30, 9 hours 48 minutes ago

Torq Completes $1.7 Million Private Placement
Published on 09/16/2026 at 16:55, 14 hours 23 minutes ago

CORRECTION FROM SOURCE: SLAM Reports 1.60% Copper Equivalent Over 14.45 Meters in Hole GW26-33; Trenching Gold-Antimony Targets on Moose Lake Project
Published on 09/16/2026 at 15:00, 16 hours 18 minutes ago

2026 Canada's Top 40 Under 40(R) Honourees Announced
Published on 09/16/2026 at 14:00, 17 hours 18 minutes ago

Ameriwest Awaits Bornite Core Assay Results and Provides Q3 2026 Corporate Update

View all ACCESSWIRE

EQS Group

Published on 09/17/2026 at 07:00, 17 minutes ago

Helvetia Baloise delivers strong half-year operating results and fast integration progress while maintaining excellent capitalisation
Published on 09/17/2026 at 07:00, 18 minutes ago

MCH Group continues its progress with a strong first half year result, further strengthening profitability
Published on 09/17/2026 at 07:00, 18 minutes ago

AEVIS VICTORIA SA: Publication of the Half-Year Report 2026 – Significant improvement in Swiss Medical Network’s profitability – Hospitality segment records encouraging results
Published on 09/17/2026 at 07:00, 18 minutes ago

MindMaze Therapeutics Announces MindMotion Lite to Expand Home-Based Neurorehabilitation
Published on 09/17/2026 at 04:25, 2 hours 52 minutes ago

Zhou Jianjun from Huawei: Building a Grid-Interactive AIDC Solution to Maximize Tokens Per Watt

Les Echos

Published on 09/16/2026 at 20:46, 10 hours 31 minutes ago

LNA SANTE : 2026 First Half Results
Published on 09/16/2026 at 17:45, 13 hours 33 minutes ago

5th edition of “On the way up” show
Published on 09/16/2026 at 17:45, 13 hours 33 minutes ago

Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 1 day ago

bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
Published on 09/15/2026 at 18:00, 1 day 13 hours ago

Report on the Combined General Meeting of the 10th of September 2026

View all LES ECHOS COMFI WIRE